Childn w/ history of Guillain-Barré syndrome or brachial neuritis following receipt of prior vaccine containing tetanus toxoid; current, or history of, allergic reaction following Tetraxim inj; adolescents of childbearing potential. Do not administer intravascularly. Immune response may be diminished in childn w/ poor immune defences, or if treated w/ corticosteroids, cytotoxic medicines, radiotherapy or other medicines that may weaken the immune system; wait until the end of treatment/disease before vaccinating. Vaccination is recommended in patients w/ chronic immunodeficiency eg, HIV infection. Risk of bleeding during IM administration in childn w/ blood disorders (eg, thrombocytopenia) or clotting disorders. Carefully evaluate giving of further doses in case of the following events after a previous Tetraxim vaccination: Fever ≥40℃ (not due to another identifiable cause), collapse or shock-like state w/ hypotonic-hyporesponsive episode, &/or persistent inconsolable crying lasting ≥3 hr, occurring w/in 48 hr of vaccination; convulsions w/ or w/o fever, occurring w/in 3 days of vaccination. Monitor temp for 48 hr after vaccination in childn w/ history of febrile convulsions unrelated to a previous vaccination. Administer Tetraxim & HIB conjugate vaccine into 2 separate inj sites & on different days in case of oedema in the lower limbs following previous HIB-containing vaccine. Contains phenylalanine.
Sign Out
